Key result
Alternate-day rosuvastatin matches daily dosing for LDL-C reduction at 12 weeks.
Why the study?
Alternate-day statin therapy has been proposed as a cost-effective strategy to maintain lipid control while potentially reducing adverse effects, but comparative data with daily dosing remain limited.
Does alternate-day rosuvastatin dosing provide equivalent lipid-lowering efficacy and safety compared to daily dosing in adults with dyslipidemia?
RCT (n=97)
Open-label
computer-generated random allocation software
No
Does alternate-day rosuvastatin dosing provide equivalent lipid-lowering efficacy and safety compared to daily dosing in adults with dyslipidemia?
Absolute Event Rate: -26.04% vs -32.76%
p-value: p=0.112
Alternate-day administration of rosuvastatin 10 mg or 20 mg demonstrates therapeutic equivalence and similar tolerability to daily 10 mg dosing, offering a potential cost-saving and adherence-improving strategy for dyslipidemia management.
Alternate-day rosuvastatin may suit select dyslipidemia patients; hypothesis-generating and requires confirmation in larger trials before practice change.
Background: Alternate-day statin therapy has been proposed as a cost-effective strategy tomaintain lipid control while potentially reducing adverse effects; however, comparative datawith daily dosing remain limited.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2026) conducted an RCT in Dyslipidemia (n=97). Alternate-day rosuvastatin vs. Daily rosuvastatin 10 mg was evaluated on Mean percentage change in LDL-C from baseline at 12 weeks (p=0.112). Alternate-day rosuvastatin 10 mg and 20 mg reduced LDL-C by 26.0% and 29.2% respectively, demonstrating therapeutic equivalence to daily 10 mg dosing (32.8% reduction, p=0.112) over 12 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: